EU Scaleup Fund leads a $100 million growth round for digital‑health startup Tandem Health, signaling continued EU backing of scalable health‑tech ventures
Executive summary: EU Scaleup Fund led a $100 million investment in Tandem Health, a digital‑health platform focused on remote monitoring and AI‑enabled care coordination. The round highlights the EU’s commitment to scaling home‑grown health‑tech firms and adds significant growth capital to a sector that is seeing rising demand for virtual care solutions.
Who is involved: EU Scaleup Fund (lead investor), Tandem Health (recipient), and undisclosed co‑investors participating in the round.
Likely next: Tandem Health will use the capital to expand its platform across European markets, pursue additional regulatory certifications, and potentially seek a follow‑on round within 12‑18 months.
The EU Scaleup Fund, the bloc’s vehicle for late‑stage startup financing, has taken the lead in a $100 million Series B‑style round for Tandem Health, a company that provides remote patient‑monitoring and AI‑driven care coordination. The deal adds to the fund’s recent activity, following a $400 million backing of Lovable in August, and underscores the EU’s strategy to stimulate private‑sector innovation in health technology. No regulatory conditions or contingencies were disclosed in the announcement.
What's next — scenarios
Base: steady rollout across EU (50%)
Tandem Health deploys its remote‑monitoring solution in Germany, France and Spain, generating €30 million of annual recurring revenue by end‑2027.
- Completion of CE‑mark extension for new indications by Q2 2027
- Signing of three national health‑service contracts by Q4 2026
- EU Scaleup Fund confirms follow‑on commitment of up to €20 million
Upside: global expansion and strategic M&A (30%)
With the fresh capital, Tandem Health accelerates entry into the U.S. market and acquires a complementary AI‑analytics startup, pushing ARR to €80 million by 2028.
- FDA 510(k) clearance obtained by Q3 2027
- Series C round of €150 million closed by mid‑2027
- Board approves acquisition target valuation ≤ €50 million
Downside: slower adoption and capital drag (20%)
Reimbursement delays limit uptake, resulting in ARR below €15 million by 2027 and a potential down‑round or bridge financing need.
- Negative outcome in HTA review in Italy (expected Q1 2027)
- Failure to secure at least two major payer contracts by Q2 2027
- EU Scaleup Fund signals reduced future health‑tech allocations
What to watch
- Q1 2027: Outcome of HTA assessment for Tandem Health’s remote‑monitoring bundle in Spain
- Q2 2027: Expected CE‑mark update for AI‑driven triage module
- Mid‑2027: Announcement of any follow‑on investment from EU Scaleup Fund or other EU‑backed funds
- End‑2027: Publication of Tandem Health’s audited FY 2027 financials (revenue and cash‑burn)
- Q3 2027: Potential FDA pre‑submission meeting for U.S. market entry
Timeline
- — EU Scaleup Fund leads $100m Tandem Health raise (Sifted — EU startups)
- — Lovable raises $400m backed by EU’s Scaleup Fund (Sifted — EU startups)
- — Exclusive: France seeks to block UK role in €5bn EU Scaleup Fund (Sifted — EU startups)
Analysis — what this means
Likely next events
- Q1 2027: HTA decision in Spain (reimbursement pathway)
- Q2 2027: CE‑mark amendment submission for AI triage
- Mid‑2027: Possible EU Scaleup Fund follow‑on commitment announcement
- End‑2027: Tandem Health FY 2027 results release
Sectors affected
- Digital health / remote patient monitoring
- Health‑tech AI analytics
- European venture‑capital late‑stage funding
Regulatory implications
- EU Scaleup Fund investments must comply with EU State Aid rules; no adverse findings reported
- Any future public‑sector co‑investment could trigger additional transparency reporting under the EU Transparency Register
- Tandem Health’s expansion will need to navigate national HTA and reimbursement frameworks in target EU countries
Historical parallels
- EU Scaleup Fund backed Lovable’s €400 million Series C in August 2026 (same fund, late‑stage health‑tech focus)
- In 2023, the European Innovation Council’s EIC Fund led a €120 million round for bio‑tech firm CureVac, showing a pattern of EU‑funded mega‑rounds in health sectors
Key entities
Sources
- EU Scaleup Fund leads $100m Tandem Health raise — Sifted — EU startups
- Lovable raises $400m backed by EU’s Scaleup Fund — Sifted — EU startups
- Exclusive: France seeks to block UK role in €5bn EU Scaleup Fund — Sifted — EU startups